The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot # / Exp Date	NDC	UPC
CATAPRES TAB 0.1MG 100	956626 01/31/2022; 861346 01/31/2022; 859015 01/31/2021; 761544 01/31/2021	00597000601	30597000601
CATAPRES TAB 0.2MG 100	C34139 11/30/2021; 861135 11/30/2021	00597000701	30597000701
CATAPRES TAB 0.3MG 100	954953 01/31/2022	00597001101	30597001101

Boehringer Ingelheim is recalling the above item/lots due to identification of extraneous peak seen in dissolution testing. This recall is to the retail level. Affected product started shipping March 29, 2018.